A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines.
Ashish H ShahRobert SuterPavan GudoorTara T Doucet-O'HareVasileios StathiasIahn CajigasMacarena de la FuenteVaidya GovindarajanAlexis A MorellDaniel G EichbergEvan M LutherVictor M LuJohn HeissRicardo J KomotarMichael E IvanStephan SchurerMark R GilbertNagi G AyadPublished in: Neuro-oncology advances (2021)
Our studies suggest that reversal of glioblastoma disease signature correlates with drug potency for various GBM subtypes. This multiparametric approach may set the foundation for an early-phase personalized -omics clinical trial for glioblastoma by effectively identifying drugs that are capable of reversing the disease signature and have favorable pharmacokinetic and safety profiles.